Consolidated net sales for the fiscal year ending March 2026 were \u00a5170.71 billion, an increase of 6.6% YoY. Operating profit was \u00a535.49 billion, and net income attributable to owners of the parent was \u00a529.72 billion. The company maintained steady performance driven by growth in new pharmaceuticals and overseas royalties.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4516","jir_company_name":"Nihon Shinyaku Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-05-15","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4516-20260515-01.pdf","jir_short_summary":"Consolidated net sales for the fiscal year ending March 2026 were \u00a5170.71 billion, an increase of 6.6% YoY. Operating profit was \u00a535.49 billion, and net income attributable to owners of the parent was \u00a529.72 billion. The company maintained steady performance driven by growth in new pharmaceuticals and overseas royalties.","jir_summary":"### Performance Overview\nFor the fiscal year ending March 2026, consolidated sales amounted to \u00a5170.71 billion, an increase of 6.6% YoY, primarily driven by expanded sales of new pharmaceuticals and increased overseas royalty income. Operating income was approximately \u00a535.49 billion, remaining almost flat, while net income attributable to shareholders declined by 8.7% to \u00a529.72 billion due to increased corporate taxes. Segments-wise, both the pharmaceuticals and functional foods businesses saw revenue growth. The company continues to expect growth through new drug launches and overseas expansion. R&D efforts are also active, with numerous clinical trials underway.\n\n### Outlook and Shareholder Returns\nForecasts for the fiscal year ending March 2027 project consolidated sales of \u00a5200.00 billion, operating income of \u00a538.00 billion, and net income attributable to owners of the parent of \u00a530.30 billion. The company plans to maintain an annual dividend of \u00a5124 per share, ensuring stable shareholder returns. It aims to accelerate new drug development and overseas expansion while balancing research investment and profit sharing to achieve sustainable growth.","jir_financial_highlights":"Sales Revenue: \u00a5170.71 billion (YoY +6.6%)\nOperating Income: \u00a535.49 billion (Increase of 0.1% compared to previous year)\nNet Income Attributable to Parent Company Owners: \u00a529.72 billion (Decreased by 8.7% compared to previous year)","jir_category":"","jir_hashtags":"#NihonShinyaku, #IRResults, #JapaneseStocks","jir_key_figures":"Sales Revenue: \u00a5170.71 billion (YoY +6.6%)\nNet Income Attributable to Owners of the Parent: \u00a529.72 billion (decreased by 8.7%)\nDividend: \u00a562 per share (annual total \u00a5124)","jir_meta_title":"\u3010Nihon Shinyaku\u30112026 Fiscal Year Financial Results\uff5cSales of \u00a5170.7 billion +6.6%","jir_meta_description":"Overview of Nihon Shinyaku's fiscal year ending March 2026 results. Sales of \u00a5170.7 billion, revenue growth, but profit decreased. Future growth strategies and dividends are also introduced.","jir_og_title":"\u3010Nihon Shinyaku\u30112026 Fiscal Year Financial Results\uff5cSales of \u00a5170.7 billion +6.6%","jir_og_description":"Detailed explanation of Nihon Shinyaku's 2026 fiscal year results and future outlook. Information on continuous growth through new drugs and overseas expansion.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Sales Trend\", \"jir_chart_json_data\": \"{\\\"type\\\": \\\"line\\\", \\\"data\\\": {\\\"labels\\\": [\\\"2024\\\",\\\"2025\\\",\\\"2026\\\"], \\\"datasets\\\": [{\\\"label\\\": \\\"Sales Revenue (\u00a5100 million)\\\", \\\"data\\\": [1602, 1607, 1707], \\\"borderColor\\\": \\\"#36A2EB\\\", \\\"fill\\\": false}]}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\": \\\"line\\\", \\\"data\\\": {\\\"labels\\\": [\\\"2024\\\",\\\"2025\\\",\\\"2026\\\"], \\\"datasets\\\": [{\\\"label\\\": \\\"Operating Income (\u00a5100 million)\\\", \\\"data\\\": [354, 354, 355], \\\"borderColor\\\": \\\"#FF6384\\\", \\\"fill\\\": false}]}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\": \\\"pie\\\", \\\"data\\\": {\\\"labels\\\": [\\\"Pharmaceuticals\\\", \\\"Functional Foods\\\"], \\\"datasets\\\": [{\\\"data\\\": [1484, 223], \\\"backgroundColor\\\": [\\\"#4BC0C0\\\", \\\"#FFCE56\\\"]}]}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Profit Margin Analysis\", \"jir_chart_json_data\": \"{\\\"type\\\": \\\"bar\\\", \\\"data\\\": {\\\"labels\\\": [\\\"Gross Profit\\\", \\\"Operating Profit\\\"], \\\"datasets\\\": [{\\\"label\\\": \\\"Ratio (%)\\\", \\\"data\\\": [113, 20], \\\"backgroundColor\\\": [\\\"#36A2EB\\\", \\\"#FF6384\\\"]}]}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Forecast vs. Actual Comparison\", \"jir_chart_json_data\": \"{\\\"type\\\": \\\"bar\\\", \\\"data\\\": {\\\"labels\\\": [\\\"2026 Actual\\\", \\\"2027 Forecast\\\"], \\\"datasets\\\": [{\\\"label\\\": \\\"Sales Revenue (\u00a5100 million)\\\", \\\"data\\\": [1707, 2000], \\\"backgroundColor\\\": \\\"#4BC0C0\\\"}, {\\\"label\\\": \\\"Net Income (\u00a5100 million)\\\", \\\"data\\\": [297, 303], \\\"backgroundColor\\\": \\\"#FF6384\\\"}]}}\"}]","ir_related_company":7976,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-51919","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n